Figure - PMC

Skip to main content

An official website of the United States government

Here's how you know

Here's how you know

Official websites use .gov
A .gov website belongs to an official government organization in the United States.

Secure .gov websites use HTTPS
A lock ( ) or https:// means you've safely connected to the .gov website. Share sensitive information only on official, secure websites.

View full-text article in PMC

. 2022 Nov 9;13(11):942. doi: 10.1038/s41419-022-05393-5

Search in PMC
Search in PubMed
View in NLM Catalog
Add to search

© The Author(s) 2022

Open Access This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The images or other third party material in this article are included in the article’s Creative Commons license, unless indicated otherwise in a credit line to the material. If material is not included in the article’s Creative Commons license and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this license, visit http://creativecommons.org/licenses/by/4.0/.

PMC Copyright notice

Fig. 6 — A HOXA11-AS knockdown affecting the sensitivity of glioma cells to H₂O₂ was verified by CCK-8 assay. B Schematic representation of the use of MLH-carrying nanoparticles (NPs) for producing reactive oxygen species (ROS). C HOXA11-AS knockdown affecting the sensitivity of glioma and patient-derived primary GBM cells to ROS produced by NPs was determined via CCK-8 assay in vitro. D The scheme of tumor inoculation and systemic injection. Bioluminescent images (E) and bioluminescent intensity (F) of the glioma-bearing mice 7, 14, 21, and 28 days after treatment with NPs, Lv-shHOXA11-AS or cotreatment with NPs and Lv-shHOXA11-AS. G Kaplan-Meier survival analysis of mice bearing orthotopically transplanted U87 cells. Group 1: treated with PBS and Lv-shNC (control). Group 2: treated with NPs alone (13.33 μmol/kg, i.p. injection). Group 3: treated with Lv-shHOXA11-AS alone (Intracranial implantation of U87 cells infected with HOXA11-AS shRNA lentivirus). Group 4: cotreated with Lv-shHOXA11-AS and NPs (Intracranial implantation of U87 cells transfected with Lv-shHOXA11-AS lentivirus and 13.33μmol/kg NPs, i.p. injection). ***P < 0.001, ****P < 0.0001.